NCT05030077 is a Phase 2 clinical trial of Anlotinib in Urothelial Carcinoma, sponsored by Tianjin Medical University Second Hospital.

Who is sponsoring NCT05030077?

NCT05030077 is sponsored by Tianjin Medical University Second Hospital.

What drugs are being tested in NCT05030077?

Interventions in NCT05030077: Anlotinib, Cisplatin, Carboplatin, Gemcitabine.

What condition does NCT05030077 study?

NCT05030077 studies Urothelial Carcinoma, Anlotinib, Urogenital Neoplasms, Cisplatin, Carboplatin, Gemcitabine, Antineoplastic Agents.

Is NCT05030077 still recruiting?

NCT05030077 is currently status unknown. Last updated 1 September 2021.

Last reviewed 2021-09-01 · How we verify

NCT05030077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Status unknown Phase 2 Last updated 1 September 2021

What this trial tests

Phase 2 trial testing Anlotinib in Urothelial Carcinoma in 53 participants. Status unknown.

Timeline

1 October 2021

Primary endpoint
1 September 2023

1 September 2024

Quick facts

Lead sponsor	Tianjin Medical University Second Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	53
Start date	1 October 2021
Primary completion	1 September 2023
Estimated completion	1 September 2024
Sites	1 location across China

Drugs / interventions tested

Anlotinib — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Urothelial Carcinoma — all drugs for Urothelial Carcinoma →
Anlotinib — all drugs for Anlotinib →
Urogenital Neoplasms — all drugs for Urogenital Neoplasms →
Cisplatin — all drugs for Cisplatin →

Sponsor

Tianjin Medical University Second Hospital

Who can join

Adults 18 to 75, any sex, with Urothelial Carcinoma or Anlotinib. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Landscape of targeted therapies for advanced urothelial carcinoma.
Shang S, Zhang L, Liu K, Lv M, et al · · 2024 · cited 2× · PMID 38966172 · DOI 10.37349/etat.2024.00240

Verify or expand the search:

Other trials of Anlotinib

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting

Other recruiting trials for Urothelial Carcinoma

Currently open trials in the same condition.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting

Other Tianjin Medical University Second Hospital trials

Trials by the same sponsor.

NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07321197 — Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Rand · NA · not yet recruiting
NCT07321210 — Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma · NA · recruiting
NCT07233252 — Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05030077 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Second Hospital
Last refreshed: 1 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05030077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing